Why EMA Should Provide Clearer Guidance on the Authorization of NBCDs in Generic and Hybrid Applications
Expert Review of Clinical Pharmacology - United Kingdom
doi 10.1080/17512433.2017.1274652
Full Text
Open PDFAbstract
Available in full text
Date
December 26, 2016
Authors
Publisher
Informa UK Limited